Academic History
Dima El-Sharkawi, MB, BS, MA, PhD, MRCP, FRCPath, is a Consultant Hematologist at the The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, UK.
Dr El-Sharkawi studied medicine at the University of Cambridge, Cambridge, UK, followed by post-graduate training in Hematology at University College London Hospital, London, UK. She is involved in research in epigenetic related prognostic factors in acute myeloid leukaemia (AML) at UCL Cancer Institute, London, UK.
Dr El-Sharkawi won the EHA Clinical Research Fellowship in 2017 and is clinical lead of the Specialist Integrated Haematological Malignancy Diagnostic Services at The Royal Marsden. She is also a member of the NCRI national lymphoma and chronic lymphocytic leukemia (CLL) trials groups and has co-authored national guidelines for the diagnosis and management of T-cell lymphoma and Waldenstrom macroglobulinaemia.
Speaking on targeted agents and trial endpoints in the treatment of CLL
Dr El-Sharkawi has a special research interest in CLL, rare leukaemias and lymphomas. She speaks on targeted agents for the treatment of CLL, including BTK inhibitors and degraders, as well as trial endpoints such as measurable residual disease (MRD) eradication.
